is topical ghk cu fda approved GHK-Cu FDA-Approved? - News GHK-Cu Topical Spray - Wells

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial Connor Iapoce Key Takeaways CagriSema achieved a 22.7% weight loss in 68 weeks, surpassing placebo and individual components but not meeting the 25% target

AuNPs are clusters of particles measuring between 1 and 100 nm, featuring gold cores enveloped in surface coatings

In pulmonary fibrosis studies using bleomycin-induced injury in mice, doses of 2.6-260 g/mL/day administered every other day from day 4-21 reduced inflammatory cell infiltration, decreased interstitial thickness, and reduced TNF- and IL-6 expression

Summary: Cagrilintide and retatrutide are investigational injectable medicines being studied for obesity and type 2 diabetes in men, targeting multiple hormonal pathways to reduce appetite, improve blood glucose control, and increase energy expenditure, but neither is currently licensed in the UK